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Background: Recent trends in vitamin K antagonists (VKA) use in non-valvular atrial fibrillation (NVAF) are useful to
evaluate the potential improvement in management of NVAF since the introduction of new oral anticoagulants.
Our objective was therefore to describe the contemporary VKA treatment patterns following NVAF diagnosis.
Methods and Results: We used the computerized databases of the Régie de l’assurance maladie du Québec
(RAMQ), responsible for administering the universal health care services for all its residents, to identify a
population-based cohort of 135,241 patients with an incident diagnosis of NVAF during 2000–2009 and
RAMQ medication coverage.
Following NVAF diagnosis, 47.1 % of the patients were prescribed VKA, 35.5 % received an antiplatelet only, and
17.4 % did not initiate antithrombotic therapy. The proportion of patients initiating VKA within 3 months of diagnosis
increased from 33 % to 39 % over the 10-year study period, mainly driven by a higher proportion of treated patients
aged 80 or more (from 29 % to 41 %). At the end of the study period, women were prescribed VKA as frequently as
men, except in the subgroup of patients with a low risk of ischemic stroke. The median time from VKA initiation to the
first discontinuation varied greatly according to the definition of discontinuation, ranging from 11 months to 5.7 years.
Conclusion: Although VKA remain underused after NVAF diagnosis, there has been an increase in VKA treatment over
the last decade, particularly among older patients. Also the gap in treatment between men and women has been
closing within the last decade. Once initiated, most VKA interruptions were temporary rather than definitive.
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Anticoagulants are prescribed to prevent ischemic stroke
in patients with non-valvular atrial fibrillation (NVAF)
[1]. These include vitamin K antagonists (VKA) such as
warfarin that have several side-effects including bleeding,
drug-drug interactions, and a narrow therapeutic win-
dow that necessitates monitoring to keep patients within
the recommended INR range. Therefore, despite proven
effectiveness of anticoagulation in the prevention of
thromboembolic events, many patients with NVAF* Correspondence: samy.suissa@mcgill.ca
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that VKA are also underused in the subgroup of patients
with a high risk of ischemic stroke [2].
The recent introduction of new oral anticoagulants in
the market may improve the overall management of pa-
tients diagnosed with NVAF. Indeed, based on results of
randomised controlled trials, these new molecules are as
effective as VKA in preventing ischemic stroke while
producing less intracerebral haemorrhage and being
more convenient to use [3]. In order to evaluate their
impact both in terms of the proportion of patients initi-
ating anticoagulation after NVAF diagnosis and long-
term compliance to treatment, updated estimates of
anticoagulation patterns with VKA are necessary for
meaningful comparison. However, few studies have
assessed long-term anticoagulation management withis distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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time.
The objectives of this study were therefore to describe
the VKA treatment patterns following NVAF diagnosis
in a population-based cohort with long-term follow-up,




This study was conducted using the computerized data-
bases of the Régie de l'assurance maladie du Québec
(RAMQ), the Maintenance et exploitation des données
pour l’étude de la clientèle hospitalière (MED-ÉCHO),
and the Institut de la statistique du Québec (ISQ).
Health care coverage is mandatory for all Québec resi-
dents except visitors, non-Canadian students, and indi-
viduals residing outside of Québec for more than
183 days in the year who are not eligible for coverage.
The RAMQ, which is responsible for administering
these universal health care services, maintains three
computerised databases. The demographic database
contains the age, sex and postal code of all individuals
registered. The medical services database contains infor-
mation on the medical services, including nature of the
service rendered, specialty of treating and referring phys-
ician, date and location, as well as the diagnostic code of
the service (International Classification of Diseases, 9th
Revision, Clinical Modification (ICD-9-CM) or enhanced
version of ICD-10 for Canada ICD-10-CA). This pro-
gram is universal for all Québec residents and is fee-for-
service. The prescription database contains information
on out-patient prescription medications including name,
dose and amount of drug dispensed, date, prescribed
number of days of treatment, and whether it was a refill
or a new prescription. This fee-for-service program (the
pharmacy claims reimbursement for the drugs dis-
pensed) covers all individuals 65 years of age and older,
welfare recipients, and since 1996, extends to all Québec
residents who do not have private medication insurance
or who choose to be covered by the RAMQ program.
MED-ÉCHO maintains the hospital inpatient database
which contains data pertaining to all Québec hospitalisa-
tions (including day surgery and inpatient stays), such as
date and type of admission and discharge, type of estab-
lishment, one primary and secondary diagnoses, as well
as procedure codes (with corresponding dates). Prior to
2006, diagnoses were classified according to the ICD-9-
CM and procedures were coded according to the
Canadian Classification of Diagnostic, Therapeutic, and
Surgical Procedures (CCDTC). Since 2006, diagnoses
and procedures are coded according to ICD-10-CA and
the Canadian Classification of Health Interventions
(CCI), respectively. Finally, the cause of death database,administered by ISQ, contains the date and cause of
death, as well as the establishment where the death took
place. Each of these databases contains the individual's
numéro d'assurance-maladie (health insurance number),
a unique number acquired at birth or at the time of
residency, used for record linkage within the RAMQ
databases and with MED-ECHO. The general accuracy
of linkage between the prescription and the medical
services databases was found to be 98.2 %, unfeasible
linkages arising primarily from name changes, and the
quality of the data has been documented [4, 5].
Cohort definition
From the source population of all individuals in the
RAMQ database, we first identified all patients, at least
18 years of age, with an inpatient or outpatient diagnosis
for atrial fibrillation (ICD-9: 427.3, 427.31, 427.32; ICD-
10: I48, I48.0, I48.1) between January 1, 2000 and De-
cember 31, 2009. Cohort entry (time zero) for all pa-
tients was defined at the date of the first diagnosis of
NVAF. If the diagnosis occurred during a hospitalisation,
cohort entry was set as the date of hospital discharge.
To confirm the incident nature of the NVAF diagnosis,
all subjects with any mention of AF in the two years
prior to cohort entry diagnosis were excluded. Patients
with a history of valvular aortic or mitral heart disease,
previous valvular repair, or hyperthyroidism (either a
treatment or a diagnosis) in the two years prior to co-
hort entry were also excluded. All cohort members were
required to have RAMQ medication coverage for at least
two years prior to cohort entry in order to provide suffi-
cient baseline information on comorbidities and prior
medication use. In addition, we excluded all patients
with a prescription for VKA in the year prior to cohort
entry. All cohort members were followed until RAMQ
deregistration, death or end of the study period
(December 31, 2009), whichever occurred first. The occur-
rence of death was determined from RAMQ and ISQ.
MED-ÉCHO was used to identify in-hospital deaths.
Exposure definition
To assess treatment patterns, all outpatient prescriptions
for oral anticoagulants and antiplatelet agents (such as
aspirin and clopidogrel) dispensed during follow-up
were identified. All oral anticoagulants prescriptions
were vitamin K antagonists (VKA) and will therefore be
referred to as VKA. For each prescription, the date of
dispensing together with product name, formulation,
dose and duration was obtained. The duration of
exposure to each drug was computed by assessing the
continuity of successive prescriptions, considered as
continuous use if the end of a prescription was followed
by the start of the next prescription of the drug. To
account for delays in refilling and reduced patient
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of each prescription (100 % of the duration of that pre-
scription) in assessing continuity of use. Thus, the dur-
ation of continuous use was the time between the date
of the start of the first prescription after the diagnosis of
NVAF and the last dispensing for which gaps between
two repeated prescriptions were less than 100 % of the
first of the two. A 100 % grace period was chosen as the
median duration of individual prescriptions was only
10 days for VKA. Sensitivity analyses with the grace
period set to 30 and 60 days were also carried out in
order to assess the impact of different grace periods on
the estimated duration of use until first discontinuation.
Since RAMQ does not collect data on inpatient pre-
scriptions, this study only provides data on outpatient
medication use patterns.
Data analysis
The study cohort was characterised by age, sex, comor-
bidities, Charlson comorbidity index, CHADS2 and
CHA2DS2-VASc risk scores [6, 7] at the time of cohort
entry using descriptive statistics. Comorbidities were
measured during the 2 years prior to cohort entry.
Kaplan-Meier technique was used to estimate the me-
dian time from NVAF diagnosis to VKA initiation and
the median duration of initial use until first treatment
interruption, modified for competing risks to account
for deaths occurring during follow-up [8], and censored
at the date of major bleeding [8]. Cox proportional haz-
ards models were used to estimate the hazard ratio (HR)
of treatment delay and treatment duration as a function of
baseline patient characteristics, including age, sex, and
baseline comorbidities. CHADS2 and CHA2DS2-VASc risk
scores were not included in multivariate models in order
to assess the independent effect of risk factors composing
these scores. Follow-up was censored at the date of death,
major bleeding, or the end of the study period (or at
3 months when assessing treatment delay). To assess
trends of VKA initiation following NVAF over the 10-year
study period, a logistic regression model was used with ad-
justment for age and CHADS2 score.
Confidence intervals were calculated using a signifi-
cance level of 5 %. All statistical procedures were per-
formed using SAS version 9.2 (SAS Institute Inc., Cary,
North Carolina).
Results
The source population included 309,556 subjects with at
least one atrial fibrillation diagnosis code during the
period 2000-2009. From these, we identified 135,241
patients with a first NVAF diagnosis, satisfying cohort
inclusions and exclusions, and having drug insurance
coverage for a minimum of two years at the time of
cohort entry (Fig. 1). Table 1 describes the baselinecharacteristics of this incident NVAF cohort. NVAF was
a hospital diagnosis in 47.8 % of the patients and the
mean follow-up was 3.3 years. The mean age at NVAF
diagnosis was 75.1 years, 74.8 % of the patients were
70 years or older at diagnosis, and 47.9 % were males.
Women were older at NVAF diagnosis, and had a higher
CHADS2 score at baseline. However, the prevalence of
most comorbidities such as myocardial infarction, dia-
betes, hyperlipidemia, and chronic renal failure was
higher in males compared to women. Patient initiating
an antithrombotic treatment within 3 months following
NVAF diagnosis were older and had more cardio- and
cerebrovascular comorbidities than patients who were
not prescribed VKA or antiplatelets.
Following NVAF diagnosis, 47.1 % of the patients were
prescribed VKA (5.9 % in combination with an antiplate-
let and 15.3 % switching from antiplatelet to VKA or
adding VKA), 35.5 % received an antiplatelet only, and
17.4 % did not initiate an antithrombotic therapy. The
proportion of patients prescribed VKA increased with
CHADS2 score. It was 37.8 % for a score of 0, 47.7 % for
score of 1, and 49.1 % for patients with a CHADS2
score ≥ 2. Most patients initiating VKA did so in the
15 days following NVAF diagnosis, regardless of age,
sex, and CHADS2 score. The proportion of patients ini-
tiating VKA within 3 months of diagnosis increased
from 33.5 % to 39 % over the 10-year study period inde-
pendently of age and CHADS2 score (p < 0.0001). This
increased use of VKA was mainly driven by a higher
proportion of treated patients aged 80 or more (from
29 % to 41 %) (Fig. 2). At the end of the study period,
women were prescribed VKA as frequently as men
shortly after NVAF diagnosis, except in the subgroup of
patients with a low risk of ischemic stroke (Figs. 3 and
4). The hazard ratios of initiating VKA within 3 months
of NVAF diagnosis according to baseline characteristics
are presented in Table 2. Older patients as well as those
with a previous ischemic stroke, congestive heart failure,
or cardiovascular medication use were more likely to ini-
tiate VKA in the first 3 months after diagnosis. Men
were also slightly more likely to initiate VKA shortly
after NVAF diagnosis than women. However, when
restricting the analysis to patients 75 years or older,
there was no difference between men and women (HR
1.01, 95 % CI 0.99-1.04). As expected, patients with a
prior bleeding event, dementia, liver disease, or chronic
renal failure were less likely to initiate VKA.
The estimated median time from VKA treatment initi-
ation to the first discontinuation was 11.1 months (95 %
CI 10.9- 11.4) for VKA (Fig. 5). However, 79 % of the pa-
tients who discontinued VKA had a new prescription
after a median time of 35 days. In sensitivity analyses,
changing the grace period to 30 and 60 days led to sub-
stantial variation in duration of VKA use until first
Fig. 1 Details of incident non-valvular atrial fibrillation (NVAF) cohort definition
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5.7 years, respectively (Fig. 5). With a grace period of
60 days, still 61 % of the patients resumed VKA treat-
ment after a median time of 87 days.
The median duration of VKA use until first discon-
tinuation varied only slightly with CHADS2 score (data
not shown). In multivariate analysis, older patients and
those with a prior ischemic stroke or transient ischemic
attack were less likely to discontinue VKA (Table 3).
Restricting the analysis to patients 75 years or older, age
and sex were not determinants of the first VKA
discontinuation.
A total of 4,621 patients (3.4 % of the patients in the
cohort) experienced a major bleeding event in the year
following NVAF diagnosis. Among them, 1,705 patients
(36.9 %) had received a VKA prescription within one
month preceding this bleeding event and 1,427
(30.9 %) an antiplatelet. Among those on VKA, 362
(21.2 %) died within 3 months following the major
bleeding, 819 (48.0 %) received at least one VKA pre-
scription, 279 (16.4 %) an antiplatelets prescription,and the remaining 245 (14.4 %) did not restart any
antithrombotic treatment.
Discussion
In this large population-based cohort of patients diag-
nosed with incident NVAF, around 40 % of patients initi-
ated VKA in the year following diagnosis, mostly within
15 days after diagnosis. The proportion of patients initi-
ating VKA shortly after diagnosis, i.e. in the first
3 months increased over the 10-year study period, with
up to 39 % of patients diagnosed in 2008 being treated
with VKA. This increased prescribing over time was
greater for women and older patients. The main deter-
minants of VKA initiation shortly after NVAF diagnosis
were age and a history of cerebrovascular event. Overall,
there were only minor differences in rates of initiation
or discontinuation of VKA between men and women,
especially in older patients.
Underuse of oral anticoagulation therapy in patients
with atrial fibrillation has been constantly reported in
the literature with recent estimations of patients treated
Table 1 Baseline characteristics of the incident NVAF cohort




N (%) N (%) N (%) N (%) N (%) N (%)
Cohort size 135,241 64,786 (47.90) 70,455 (52.10) 34,659 (25.63) 51,794 (38.30) 48,788 (36.07)
Age, mean (SD) 75.09 (11.41) 73.29 (11.30) 76.73 (11.26) 72.54 (14.65) 75.95 (8.85) 75.98 (10.92)
18-49 4,526 (3.35) 2,643 (4.08) 1,883 (2.67) 2,918 (8.42) 525 (1.01) 1,083 (2.22)
50-59 6,770 (5.01) 3,948 (6.09) 2,822 (4.01) 2,558 (7.38) 1,697 (3.28) 2,515 (5.15)
60-69 22,730 (16.81) 12,736 (19.66) 9,994 (14.18) 6,027 (17.39) 8,408 (16.23) 8,295 (17.00)
70-79 51,018 (37.72) 26,376 (40.71) 24,642 (34.98) 10,977 (31.67) 22,533 (43.51) 17,508 (35.89)
80-89 40,769 (30.15) 16,403 (25.32) 24,366 (34.58) 9,369 (27.03) 16,503 (31.86) 14,897 (30.53)
≥90 9,428 (6.97) 2,680 (4.14) 6,748 (9.58) 2,810 (8.11) 2,128 (4.11) 4,490 (9.20)
Comorbidities
Hypertension 83,393 (61.66) 36,683 (56.62) 46,710 (66.30) 17,682 (51.02) 33,651 (64.97) 32,060 (65.71)
Myocardial infarction 27,909 (20.64) 16,186 (24.98) 11,723 (16.64) 3,475 (10.03) 10,081 (19.46) 14,353 (29.42)
Congestive heart failure 27,673 (20.46) 14,025 (21.65) 13,648 (19.37) 5,035 (14.53) 11,325 (21.87) 11,313 (23.19)
Prior stroke or TIA 11,654 (8.62) 5,644 (8.71) 6,010 (8.53) 1,726 (4.98) 5,088 (9.82) 4,840 (9.92)
Prior hemorrhage 21,080 (15.59) 11,160 (17.23) 9,920 (14.08) 6,452 (18.62) 6,437 (12.39) 8,191 (16.79)
Diabetes 34,337 (25.39) 17,893 (27.62) 16,444 (23.34) 6,318 (18.23) 13,688 (26.43) 14,331 (29.37)
Hyperlipidemia 57,433 (42.47) 30,360 (46.86) 27,073 (38.43) 8,165 (23.56) 23,688 (45.74) 25,580 (52.43)
Peripheral vascular disease 16,397 (12.12) 9,857 (15.21) 6,540 (9.28) 2,667 (7.69) 5,900 (11.39) 7,830 (16.05)
Chronic renal failure 14,467 (10.70) 8,228 (12.70) 6,239 (8.86) 3,124 (9.01) 4,960 (9.58) 6,383 (13.08)
Cancer 26,479 (19.58) 15,363 (23.71) 11,116 (15.78) 8,308 (23.97) 8,538 (16.48) 9,633 (19.74)
Charlson index, median (IQR) 1 (0-3) 1 (0-3) 1 (0-2) 1 (0-3) 1 (0-2) 1 (0-3)
0 50,090 (37.04) 21,300 (32.88) 28,790 (40.86) 14,295 (41.24) 20,308 (39.21) 15,487 (31.74)
1-2 49,213 (36.39) 23,036 (35.56) 26,177 (37.15) 11,517 (33.23) 19,606 (37.85) 18,090 (37.08)
≥3 35,938 (26.57) 20,450 (31.57) 15,488 (21.98) 8,847 (25.53) 11,880 (22.94) 15,211 (31.18)
CHADS2, median (IQR) 2 (1-3) 2 (1-2) 2 (1-3) 1 (1-2) 2 (1-3) 2 (1-3)
0 19,052 (14.09) 10,719 (16.55) 8,333 (11.83) 8,280 (23.89) 5,466 (10.55) 5,306 (10.88)
1 37,744 (27.91) 19,085 (29.46) 18,659 (26.48) 10,741 (30.99) 14,355 (27.72) 12,648 (25.92)
≥2 78,445 (58.00) 34,982 (54.00) 43,463 (61.69) 15,638 (45.12) 31,973 (61.73) 30,834 (63.20)
CHA2DS2-VASc, median (IQR) 3 (2-5) 3 (2-4) 4 (3-5) 3 (2-4) 4 (3-5) 4 (3-5)
0 4,209 (3.11) 4,209 (6.50) 0 (0.0) 2,212 (6.38) 875 (1.69) 1,122 (2.30)
1 11,530 (8.53) 7,962 (12.29) 3,568 (5.06) 4,973 (14.35) 3,380 (6.53) 3,177 (6.51)
≥2 119,502 (88.36) 52,615 (81.21) 66,887 (94.94) 27,474 (79.27) 47,539 (91.78) 44,489 (91.19)
HAS-BLED, median (IQR) 2 (1-3) 2 (1-3) 2 (1-3) 1 (1-2) 2 (1-3) 2 (2-3)
≤2 96,763 (71.55) 45,097 (69.61) 51,666 (73.33) 29,400 (84.83) 37,215 (71.85) 30,148 (61.79)
≥3 38,478 (28.45) 19,689 (30.39) 18,789 (26.67) 5,259 (15.17) 14,579 (28.15) 18,640 (38.21)
Medications
Antihypertensive drugs** 99,313 (73.43) 45,477 (70.20) 53.836 (76.41) 19,384 (55.93) 40,750 (78.68) 39,179 (80.30)
NSAIDs 49,164 (36.35) 21,617 (33.37) 27,547 (39.10) 12,496 (36.05) 19,003 (36.69) 17,665 (36.21)
Statins 52,132 (38.55) 27,934 (43.12) 24,198 (34.35) 6,873 (19.83) 21,703 (41.90) 23,556 (48.28)
*Initiation within 3 months following NVAF diagnosis
**Refers to angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers and diuretics
Abbreviations: TIA transient ischemic attack, NSAIDs non-steroidal anti-inflammatory drugs
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Fig. 2 Proportion of patients initiating VKA within 3 months following NVAF diagnosis, stratified by age and calendar year of diagnosis
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horts [9–17]. Even in patients considered at high risk for
ischemic stroke, such as patients with a CHADS2 score
of 2 or more, less than 70 % of patients were treated
with VKA according to a recent systematic review when
most of these high-risk patients should be treated with
anticoagulants based on all current guidelines [18]. Our
results based on a recent large cohort of patients with
incident NVAF are in line with these previous estimates.
Indeed, only 49 % of patients with a CHADS2 score of 2
or more were prescribed VKA in our cohort. Moreover,
given that around 60 % of patients in our cohort were at
high risk of stroke (CHADS2 of 2 or more) and 28 %
were at intermediate risk, at least 60 % of our cohort
overall would be expected to be treated with oralFig. 3 Proportion of patients initiating VKA within 3 months following NVAanticoagulants using a conservative estimate. We were
able to examine prescribing trends over time, and we
found an increased use of anticoagulants after NVAF
diagnosis over the last decade, which was not explained
by the aging of the population or a different vascular risk
profile in patients diagnosed more recently. This in-
creased proportion of treated patients was mainly driven
by an increase use in older patients, those most likely to
benefit from oral anticoagulation. A recent British co-
hort study of 81,381 patients aged 60 years or older also
showed a moderate increased prescribing of VKA in pa-
tients with AF over the same 10-year study period [16].
Similarly to our finding, the highest increased was seen
in patients over 70 years old at diagnosis. It is therefore
possible that studies repeatedly showing the benefit ofF diagnosis, stratified by sex
Fig. 4 Proportion of patients initiating VKA within 3 months following NVAF diagnosis, stratified by sex, CHADS2 score, and calendar year
of diagnosis
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increased awareness of physicians through published
guidelines have led to improvement in the management
of NVAF in this population. However, anticoagulants
remained underused and the recent introduction of new
oral anticoagulants on the market may further increase
the proportion of patients with NVAF prescribed antic-
oagulation in light of their ease of use.
Sex differences in patterns of VKA use have been re-
ported in several previous studies. Indeed, it has been
showed that women, although at higher risk of ischemic
stroke in the context of AF, were less likely to be treated
with oral anticoagulant following NVAF diagnosis than
men [16, 17, 19]. However, in our study, women were
only slightly less likely to be prescribed VKA compared
to men, in accordance with a recent systematic review
and meta-analysis reporting a pooled odds ratio of 1.12
for the association between male sex and warfarin use
[20]. More importantly, we found that the proportion of
women initiating VKA after NVAF diagnosis increased
over the decade, particularly in patients with a moderate
to high risk of ischemic stroke so that there was no
more sex difference at the end of the study period in
these subgroups. A recent Canadian study restricted to
patients aged 65 or older and hospitalised with an AF
diagnosis in Québec between 1998 and 2007 found very
similar warfarin initiation between men and women in a
cohort of 83,513 patients [9]. However, the study exam-
ined prescriptions issued in the 30 days post discharge
only and did not examine trends over time.
Estimation of discontinuation of VKA in large cohorts
of patients initiating anticoagulation after NVAF diagno-
sis varies substantially in the literature. For instance, theestimated median time to the first discontinuation of
VKA was 127 days in a large US cohort of 116,969 pa-
tients with NVAF. [17] In a British cohort of 41,910 pa-
tients with chronic AF, 30 % had discontinued warfarin
within one year after treatment initiation [21]. Among
4188 patients newly starting warfarin in the anticoagula-
tion and risk factors in Atrial Fibrillation Study, 26.3 %
discontinued warfarin within the first year of therapy
[22]. These differences are likely explained by different
definitions of VKA interruption. Indeed, we showed that
the time to first treatment discontinuation varied greatly
according to the grace period definition with an esti-
mated median time of several years when using a grace
period of 60 days as opposed to a median time of
11 months when using a 100 % grace period which cor-
responds to less than 15 days for most patients in our
cohort. This variation suggests that VKA discontinuation
is often temporary rather than definitive, and that many
patients continue oral anticoagulation treatment once
initiated. Reasons for temporary interruptions of antic-
oagulation are numerous and include in particular tem-
porary interruption for minor bleeding or planned
procedure or surgery. Moreover, time to VKA treatment
discontinuation may be artificially shortened when mea-
sured using administrative databases since duration of
each prescription is imprecise and VKA treatment is fre-
quently prone to doses adjustments. In the ATRIA
study, around 25 % of patients had evidence of restarting
warfarin within 2 years after the first discontinuation,
and overall the proportion of patients prescribed war-
farin remained relatively unchanged after the first year
[22]. In our study, using a stricter definition of discon-
tinuation, the percentage of patients resuming VKA was
Table 2 Hazard ratios of characteristics associated with VKA initiation within 3 months following NVAF diagnosis
% Crude HR Adjusted HR (95 % CI)
Size, n 135,241
Age
18-29 0.45 0.22 0.23 (0.15 - 0.36)
30-39 0.83 0.45 0.45 (0.36 - 0.58)
40-49 2.06 1.00 1.00 (Reference)
50-59 5.01 1.73 1.68 (1.51 - 1.87)
60-69 16.81 2.73 2.55 (2.31 - 2.82)
70-74 17.43 3.29 3.05 (2.77 - 3.36)
75-79 20.29 3.51 3.28 (2.97 - 3.61)
80-84 18.06 3.31 3.12 (2.83 - 3.44)
85-89 12.09 2.76 2.66 (2.41 - 2.94)
≥90 6.97 1.60 1.57 (1.41 - 1.74)
Male 47.90 1.02 1.09 (1.07 - 1.11)
Comorbidities
Hypertension 61.66 1.21 1.03 (1.01 - 1.05)
Myocardial infarction 20.64 0.94 0.89 (0.87 - 0.92)
Angina pectoris 20.02 0.94 0.88 (0.86 - 0.90)
Congestive heart
failure
20.46 1.15 1.20 (1.18 - 1.23)
Prior stroke or TIA 8.62 1.22 1.25 (1.21 - 1.28)
Prior bleeding
events
Intracranial bleeding 1.00 0.56 0.55 (0.49 - 0.61)
Gastrointestinal
bleeding
5.75 0.65 0.67 (0.64 - 0.70)
Other bleeding 8.84 0.85 0.85 (0.83 - 0.88)
Diabetes 25.39 1.08 0.97 (0.95 - 0.99)
Hyperlipidemia 42.47 1.18 1.00 (0.95 - 1.05)
Vascular disease 12.12 0.94 0.87 (0.84 - 0.89)
Chronic renal failure 10.70 0.89 0.87 (0.84 - 0.90)
Complications of
alcohol abuse
3.61 0.61 0.78 (0.73 - 0.83)
Liver disease 2.53 0.67 0.80 (0.75 - 0.85)
Cancer 19.58 0.79 0.76 (0.75 - 0.78)
Coagulation defects 1.81 0.75 0.88 (0.82 - 0.95)
Predisposition to falls 15.44 0.75 0.80 (0.78 - 0.83)
Dementia/schizophrenia 8.81 0.55 0.65 (0.63 - 0.68)
Venous thromboembolism 5.47 1.37 1.48 (1.43 - 1.53)
COPD 26.65 0.94 0.93 (0.91 - 0.95)
Medications
ACE 35.62 1.21 1.12 (1.10 - 1.15)
ARB 21.28 1.25 1.12 (1.09 - 1.14)
CCB 41.51 1.27 1.19 (1.16 - 1.21)
Diuretics 50.08 1.25 1.09 (1.07 - 1.12)
Antidepressants 19.44 0.84 0.91 (0.89 - 0.94)
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Table 2 Hazard ratios of characteristics associated with VKA initiation within 3 months following NVAF diagnosis (Continued)
Antipsychotics 5.81 0.61 0.83 (0.79 - 0.87)
NSAIDs 36.35 1.01 1.00 (0.98 - 1.02)
Statins 38.55 1.19 1.05 (1.00 - 1.10)
Abbreviations: HR hazard ratio, TIA transient ischemic attack, COPD chronic obstructive pulmonary disease, ACE angiotensin-converting enzyme inhibitors, ARB
angiotensin receptor blockers, NSAIDs non-steroidal anti-inflammatory drugs
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patients discontinue VKA and even temporary interrup-
tions are of concern as they are associated with an in-
creased risk of thromboembolic event. In this context,
new oral anticoagulants may help improve the long-term
compliance to anticoagulation therapy.
Our study is based on one of the largest and most re-
cent population-based cohort of patients diagnosed with
NVAF, allowing precise and contemporary estimates of
VKA treatment patterns in a real-world setting. More-
over, our study follow-up covered the entire last decade
so that we were able to examine recent time trends in
antithrombotic treatment just preceding the introduc-
tion of new oral anticoagulants. Data for each patient,
including prescriptions, were collected prospectively,
thus avoiding the potential for recall bias inherent in
field studies. Moreover, the use of drugs was not simply
based on written prescriptions, but rather on dispensed
prescriptions actually filled by patients, which reduces
significantly misclassification of exposure. All patients in
our study had drug coverage from the province of Qué-
bec; therefore we likely captured most antithrombotic
prescriptions. However, we cannot exclude the possibil-
ity that some prescriptions were issued over the counter
especially for aspirin or out of the provincial system forFig. 5 Survival estimates of the time from VKA initiation to first discontinuaVKA, but this number is likely to be small in the context
of a chronic disease in patients with full provincial drug
coverage. Also, our study describes the out-patients
prescriptions patterns as we did not have access to in-
patients prescriptions. This may potentially leads to
underestimate the time to the first antithrombotic
treatment discontinuation if some patients have their
treatment renewed while in hospital. However, this is
unlikely to change our results as the number and length
of hospitalisations were quite small in the year following
NVAF diagnosis in our cohort study. Finally, using an
administrative database such as RAMQ, the diagnosis of
AF was based on ICD codes only and we were not able
to validate the NVAF diagnosis with electrocardiogram
or other medical data. Also, ICD 9 and 10 codes for AF
do not differentiate between paroxysmal and chronic
AF. However, using the same cohort, we previously
found incidence rates of NVAF very similar to other
contemporary cohorts using various diagnostic criteria
[23], suggesting that our cohort likely includes mostly
true incident cases of NVAF. Similarly, the identification
of patients’ comorbidities were based on ICD codes
without access to medical records and some clinical data
such as smoking and obesity are not available in the
RAMQ database.tion according to the definition of the grace period
Table 3 Hazard ratios of determinants associated with VKA discontinuation in NVAF
Factors % Crude HR Adjusted HR (95 % CI)
Size, n 63,675
Age
18-29 0.07 1.60 1.65 (1.19 - 2.29)
30-39 0.19 1.47 1.48 (1.19 - 1.84)
40-49 0.89 1.00 1.00 (Reference)
50-59 3.59 0.88 0.88 (0.79 - 0.98)
60-69 16.79 0.83 0.83 (0.76 - 0.92)
70-74 19.82 0.82 0.82 (0.75 - 0.91)
75-79 23.78 0.78 0.79 (0.72 - 0.87)
80-84 19.80 0.74 0.75 (0.68 - 0.83)
85-89 11.10 0.77 0.79 (0.71 - 0.87)
≥90 3.97 0.77 0.80 (0.71 - 0.88)
Time to treatment initiation
0 day 39.51 1.00 1.00 (Reference)
1-7 days 23.73 1.07 1.11 (1.08 - 1.13)
8-30 days 12.11 1.00 1.04 (1.01 - 1.07)
31-90 days 5.99 1.02 1.04 (0.99 - 1.08)
>90 days 18.66 1.14 1.13 (1.10 - 1.17)
Male 48.46 1.08 1.03 (1.01 - 1.05)
Comorbidities
Hypertension 64.50 0.98 0.98 (0.96 - 1.01)
Myocardial infarction 19.73 1.13 1.08 (1.05 - 1.11)
Angina pectoris 19.79 1.10 1.06 (1.04 - 1.09)
Congestive heart failure 21.15 1.06 1.02 (0.99 - 1.05)
Prior stroke or TIA 9.36 0.90 0.90 (0.87 - 0.93)
Prior bleeding events
Intracranial bleeding 0.64 1.05 1.04 (0.92 - 1.18)
Gastrointestinal bleeding 4.44 1.13 1.06 (1.01 - 1.11)
Other bleeding 7.83 1.04 1.01 (0.97 - 1.04)
Diabetes 26.00 1.03 1.01 (0.99 - 1.04)
Hyperlipidemia 44.96 1.03 1.08 (1.03 - 1.13)
Vascular disease 11.52 1.10 1.06 (1.02 - 1.09)
Chronic renal failure 9.40 1.19 1.14 (1.10 - 1.18)
Complications of alcohol abuse 2.38 1.19 1.10 (1.03 - 1.17)
Liver disease 1.85 1.20 1.09 (1.02 - 1.17)
Cancer 16.72 1.14 1.13 (1.10 - 1.16)
Coagulation defects 1.42 1.16 1.08 (0.99 - 1.17)
Predisposition to falls 12.46 1.03 1.01 (0.98 - 1.04)
Dementia/schizophrenia 4.97 1.04 1.04 (0.99 - 1.09)
Venous thromboembolism 6.36 1.20 1.16 (1.12 - 1.21)
COPD 25.52 1.07 1.03 (1.01 - 1.06)
Medications
ACE 38.49 0.99 0.97 (0.95 - 1.00)
ARB 23.56 0.99 1.00 (0.97 - 1.02)
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Table 3 Hazard ratios of determinants associated with VKA discontinuation in NVAF (Continued)
CCB 45.28 0.99 0.98 (0.96 - 1.01)
Diuretics 53.37 0.99 1.00 (0.98 - 1.02)
Antidepressants 17.18 1.03 1.02 (0.99 - 1.04)
Antipsychotics 3.64 1.07 1.03 (0.97 - 1.08)
NSAIDs 37.56 1.02 1.01 (0.99 - 1.03)
Statins 40.93 1.02 0.92 (0.88 - 0.97)
Abbreviations: HR hazard ratio, TIA transient ischemic attack, COPD chronic obstructive pulmonary disease, ACE angiotensin-converting enzyme inhibitors, ARB
angiotensin receptor blockers, NSAIDs non-steroidal anti-inflammatory drugs
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In conclusion, findings from this large population-base
cohort of patients with NVAF indicate that anticoagula-
tion is still underused even though the efficacy of VKA
in preventing thromboembolic events has been well
established. However, there was an increased proportion
of patients initiating VKA over the last decade, particu-
larly for women and older patients. Further research will
clarify whether the introduction of new oral anticoagu-
lants improve the overall therapeutic management of
patients with NVAF.
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